RecruitingPhase 1Phase 2NCT06782334

AMT-116 in Patients with Solid Tumors

Phase 1/2 Study of AMT-116 in Patients with Advanced Solid Tumors

Sponsor

Multitude Therapeutics Inc.

Enrollment

144 participants

Start Date

May 7, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

The purpose of this study is to evaluate the safety and efficacy of AMT-116 monotherapy in subjects with advanced solid tumors. The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AMT-116 for people with advanced solid tumors. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.